Eric Venker - 02 Jun 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: President & COO
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol: ROIV
Transactions as of: 02 Jun 2025
Net transactions value: -$5,822,592
Form type: 4
Filing time: 04 Jun 2025, 21:00:44 UTC
Previous filing: 22 May 2025
Next filing: 24 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Venker Eric	President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	04 Jun 2025	0001801917

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$2,310,000	+600,000	+56%	$3.85	1,677,197	02 Jun 2025	Direct
transaction	ROIV	Common Shares	Sale	$4,801,303	-433,722	-26%	$11.07	1,243,475	02 Jun 2025	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$3,022,350	+785,026	+63%	$3.85	2,028,501	03 Jun 2025	Direct
transaction	ROIV	Common Shares	Sale	$6,353,639	-566,278	-28%	$11.22	1,462,223	03 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-600,000	-6.2%	$0.000000	9,123,923	02 Jun 2025	Common Stock	600,000	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-785,026	-8.6%	$0.000000	8,338,897	03 Jun 2025	Common Stock	785,026	$3.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Content

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).